Literature DB >> 33221464

Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors.

Jensen Yeung1, Ron Vender2, Irina Turchin3, Rahul Shukla4, Catherine Maari5, Chih-Ho Hong6, Maxime Barakat7, Perla Lansang8.   

Abstract

Entities:  

Year:  2020        PMID： 33221464     DOI： 10.1016/j.jaad.2020.11.013

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  3 in total

Review 1.  Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.

Authors:  Alan Menter; Tina Bhutani; Benjamin Ehst; Boni Elewski; Abby Jacobson
Journal:  Dermatol Ther (Heidelb)       Date:  2022-06-07

Review 2.  Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis.

Authors:  Valerio Caputo; Claudia Strafella; Terenzio Cosio; Caterina Lanna; Elena Campione; Giuseppe Novelli; Emiliano Giardina; Raffaella Cascella
Journal:  Genes (Basel)       Date:  2021-09-10       Impact factor: 4.096

3.  Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways.

Authors:  M A X Tollenaere; J Hebsgaard; D A Ewald; P Lovato; S Garcet; X Li; S D Pilger; M L Tiirikainen; M Bertelsen; J G Krueger; H Norsgaard
Journal:  Br J Dermatol       Date:  2021-05-31       Impact factor: 9.302
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.